Skip to main content
Jaime Merchan, MD, Oncology, Miami, FL, Jackson Health System

JaimeRMerchanMD

Oncology Miami, FL

Genitourinary Oncology

Tenured Associate Professor of Medicine, University of Miami School of Medicine. Director, Phase 1 Clinical Trials Program, Sylvester Comprehensive Cancer Center

Dr. Merchan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Merchan's full profile

Already have an account?

Education & Training

  • Harvard University - Massachusetts Institute of Technology
    Harvard University - Massachusetts Institute of TechnologyMMSc, Translational Research, 2001 - 2003
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Internal Medicine, 1994 - 1998
  • Universidad Catolica de Santiago de Guayaquil
    Universidad Catolica de Santiago de GuayaquilClass of 1992

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1997 - 2026
  • MN State Medical License
    MN State Medical License 2003 - 2007
  • MA State Medical License
    MA State Medical License 1998 - 2005
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma  
    Robert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine

Lectures

  • Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

Authored Content

  • Notch Pathway Inhibition with LY3039478 in Soft Tissue Sarcoma and Gastrointestinal Stromal TumoursOctober 2018

Press Mentions

  • Sylvester Junior Faculty Selected for K12 Research Grants
    Sylvester Junior Faculty Selected for K12 Research GrantsMay 16th, 2023
  • Sylvester’s Course on Cancer Clinical Trials Goes National, International
    Sylvester’s Course on Cancer Clinical Trials Goes National, InternationalFebruary 15th, 2023
  • A Boost for Sylvester: DeSantis Announces $100 Million in Funding for State’s Top Cancer Centers
    A Boost for Sylvester: DeSantis Announces $100 Million in Funding for State’s Top Cancer CentersMay 18th, 2022
  • Join now to see all

Grant Support

  • Tumor And Stromal Targeting By Oncolytic VirusesNational Cancer Institute2011–2012
  • Biomarkers For VEGF And Mtor Blockade In Advanced Renal CancerNational Cancer Institute2006–2007

Professional Memberships

Other Languages

  • Spanish, Portuguese

Hospital Affiliations